BOARD OF DIRECTORS Ira Arlook Judith Brady Irwin Brass, Ph.D.

Fibrous and Mineral Content of Cosmetic Talcum Products L.

Research report Downloaded from jech.bmj.com on 3 0 M ay 2 0 0 8 Perineal use of talc and risk of ovarian cancer H Langseth,1 S E Hankinson,2 J Siemiatycki,3 E W eiderpass145 1The Cancer Registry of Norw ay, Institute of populationbased Cancer Research, Oslo, Norway; 2 Channing Laboratory, Department of Medicine, Brigham and W o m e n 's Hospital and Harvard Medical School, Boston, M A , U S A ; 3 Department of Social and Preventive Medicine, University of Montreal, Montreal, Canada; 4 Department of Medical Epidemiology and Biostatistics, Karolinska Instituted Stockholm, Sweden; 5 Samfundet Folkhalsan, Helsinki, Finland Correspondence to: E Weiderpass, The Cancer Registry of Norway, 0 3 1 0 Oslo, Norway; eliwei@ki.se Accepted 15 October 2007 ABSTRACT Ovarian cancer is one of the most common gynaecological neoplasms, especially in industrialised countries.

FILE NAME: Talc (TALC) DATE: 1972 June 15 DOC#: TALC070 DOCUMENT DESCRIPTION: Letter Barry Castleman from the US Senate with Attached Letter to US Senator from Constituent CHARLES MCC.

FILE NAME: Talc (TALC) DATE: 1973 June 4 DOC#: TALC074 DOCUMENT DESCRIPTION: Letter to the FDA from Barry Castleman /> ^ -r (202) 332-6000 CENTER FOR SCIENCE IN THE PUBLIC INTEREST 1779 Church Street, N.W.

memo record from: Dr.

JOURNAL OF AEROSOL MEDICINE Volume 3, Supplement I, 1990 Mary Ann Liebert, Inc., Publishers Overload of Lung Clearance Is Associated with Activation of Alveolar Macrophage Tumor Necrosis Factor and Fibronectin Release KEVIN E.

REGULATORY TOXICOLOGY AND PHARMACOLOGY 2 1 , 211-215 ( 1995) 1Talc: Consumer Uses and Health Perspectives Bethesda, Maryland, January 3-February 1, 1994 Co-Sponsored by: The International Society of Regulatory Toxicology & Pharm acology and The United States Food and Drug Administration Rapporteur C.

PUBLC HEALTH SLRVICE POOD AND DRUG ADMINi.STRATON : Robert K BcV.i finer, Phhft., ]>:lrecf.or O ffic e oi.

r9P*f <*&*jMPfSMPtl; Bifilfaa# 3i@*BK& 4MMf -Ie^4t1, VWltfftBl 'tlMMtje lac 649 * t M S I M m tm ?

H0AGLAN1 LONGO MODAU, DUNST a BOUNDS, LIP ATTORNEYS ai LAW 40 Paterson Street New Brunswick, NJ 08901 Tel: (732) 545-4717 Fax: (732) 545-4579 www.hoaglandlongo.com Katherine Blok Associate kblok@hoaglandlongo.com Food and Drug Administration Division of Freedom o f Information Office of the Executive Secretariat, OC 12420 Parklawn Drive ELEM-1029 Rockville, MD 20857 January 17, 2014 Re: Whittaker Clark & Daniels Our File No.: 5964698 - NJG To Whom It May Concern: This correspondence is intended to supplement our request for documents under the Freedom of Information Act, 5 U.S.C. 552, submitted electronically via FDA.gov.

A R Z N E I MSIonTdTerdEruLck- FaOusR: S C H U N G (Arzneim.

EXHIBIT IV .

MOUNT SINAI SCHOOL OF MEDICINE of The City University ofNew York P I P T H A V E N U E AND 100TH S T R E E T N E W YORK, N.Y. 10029 DepartmentofCommunityMedicine M a y 9, 1972 Mr.

/ \ .Scott Laboratories, Inc